The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16.


Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ET(A) with significant affinity for the ET(B) receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

MeSH terms

  • Administration, Oral
  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / pharmacokinetics
  • Antihypertensive Agents / pharmacology
  • CHO Cells
  • Cricetinae
  • Cricetulus
  • Drug Discovery*
  • Endothelin A Receptor Antagonists*
  • Endothelin B Receptor Antagonists*
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology*
  • Rats
  • Rats, Inbred Dahl
  • Sulfonamides / administration & dosage
  • Sulfonamides / pharmacokinetics
  • Sulfonamides / pharmacology*


  • Antihypertensive Agents
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Pyrimidines
  • Sulfonamides
  • macitentan